These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 28121670)

  • 1. Effect of antiretroviral therapy on malaria incidence in HIV-infected Ugandan adults.
    Kasirye RP; Grosskurth H; Munderi P; Levin J; Anywaine Z; Nunn A; Kamali A; Baisley K
    AIDS; 2017 Feb; 31(4):577-582. PubMed ID: 28121670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal effect of CD4 by cotrimoxazole use on malaria incidence among HIV-infected Ugandan adults on antiretroviral therapy: a randomized controlled study.
    Kasirye R; Grosskurth H; Munderi P; Levin J; Anywaine Z; Nunn A; Kamali A; Baisley K
    Malar J; 2016 Jul; 15():361. PubMed ID: 27417903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of malaria by cotrimoxazole use in HIV-infected Ugandan adults on antiretroviral therapy: a randomised, placebo-controlled study.
    Kasirye RP; Baisley K; Munderi P; Levin J; Anywaine Z; Nunn A; Kamali A; Grosskurth H
    AIDS; 2016 Feb; 30(4):635-44. PubMed ID: 26558729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-infected ugandan adults taking antiretroviral therapy with CD4 counts >200 cells/μL who discontinue cotrimoxazole prophylaxis have increased risk of malaria and diarrhea.
    Campbell JD; Moore D; Degerman R; Kaharuza F; Were W; Muramuzi E; Odongo G; Wetaka M; Mermin J; Tappero JW
    Clin Infect Dis; 2012 Apr; 54(8):1204-11. PubMed ID: 22423133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiretroviral agents and prevention of malaria in HIV-infected Ugandan children.
    Achan J; Kakuru A; Ikilezi G; Ruel T; Clark TD; Nsanzabana C; Charlebois E; Aweeka F; Dorsey G; Rosenthal PJ; Havlir D; Kamya MR
    N Engl J Med; 2012 Nov; 367(22):2110-8. PubMed ID: 23190222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of discontinuing cotrimoxazole prophylaxis among HIV infected adults on anti-retroviral therapy in Uganda (COSTOP trial): Design.
    Anywaine Z; Abaasa A; Levin J; Kasirye R; Kamali A; Grosskurth H; Munderi P; Nunn A
    Contemp Clin Trials; 2015 Jul; 43():100-4. PubMed ID: 26009024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does a significant reduction in malaria risk make lopinavir/ritonavir-based ART cost-effective for children with HIV in co-endemic, low-resource settings?
    Ahmed BS; Phelps BR; Reuben EB; Ferris RE
    Trans R Soc Trop Med Hyg; 2014 Jan; 108(1):49-54. PubMed ID: 24300443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of co-trimoxazole prophylaxis, antiretroviral therapy, and insecticide-treated bednets on the frequency of malaria in HIV-1-infected adults in Uganda: a prospective cohort study.
    Mermin J; Ekwaru JP; Liechty CA; Were W; Downing R; Ransom R; Weidle P; Lule J; Coutinho A; Solberg P
    Lancet; 2006 Apr; 367(9518):1256-61. PubMed ID: 16631881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cotrimoxazole Prophylaxis Discontinuation among Antiretroviral-Treated HIV-1-Infected Adults in Kenya: A Randomized Non-inferiority Trial.
    Polyak CS; Yuhas K; Singa B; Khaemba M; Walson J; Richardson BA; John-Stewart G
    PLoS Med; 2016 Jan; 13(1):e1001934. PubMed ID: 26731191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discontinuing cotrimoxazole preventive therapy in HIV-infected adults who are stable on antiretroviral treatment in Uganda (COSTOP): A randomised placebo controlled trial.
    Anywaine Z; Levin J; Kasirye R; Lutaakome JK; Abaasa A; Nunn A; Grosskurth H; Munderi P;
    PLoS One; 2018; 13(12):e0206907. PubMed ID: 30596666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of cotrimoxazole prophylaxis on malaria occurrence among HIV-infected adults in West Africa: the MALHIV Study.
    Eholié SP; Ello FN; Coffie PA; Héma A; Minta DK; Sawadogo A
    Trop Med Int Health; 2017 Sep; 22(9):1186-1195. PubMed ID: 28653454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of HIV and malaria parasites co-infection on immune-hematological profiles among patients attending anti-retroviral treatment (ART) clinic in Infectious Disease Hospital Kano, Nigeria.
    Jegede FE; Oyeyi TI; Abdulrahman SA; Mbah HA; Badru T; Agbakwuru C; Adedokun O
    PLoS One; 2017; 12(3):e0174233. PubMed ID: 28346490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Virologic and immunologic outcomes of HIV-infected Ugandan children randomized to lopinavir/ritonavir or nonnucleoside reverse transcriptase inhibitor therapy.
    Ruel TD; Kakuru A; Ikilezi G; Mwangwa F; Dorsey G; Rosenthal PJ; Charlebois E; Havlir D; Kamya M; Achan J
    J Acquir Immune Defic Syndr; 2014 Apr; 65(5):535-41. PubMed ID: 24326597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of switching to second-line antiretroviral therapy and associated factors in children with HIV: an international cohort collaboration.
    Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Global Cohort Collaboration
    Lancet HIV; 2019 Feb; 6(2):e105-e115. PubMed ID: 30723008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Malaria Parasitemia and Parasite Density in Antiretroviral-Treated HIV-Infected Adults Following Discontinuation of Cotrimoxazole Prophylaxis.
    Ottichilo RK; Polyak CS; Guyah B; Singa B; Nyataya J; Yuhas K; John-Stewart G; Waitumbi JN
    J Infect Dis; 2017 Jan; 215(1):88-94. PubMed ID: 28077587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial.
    Duvivier C; Ghosn J; Assoumou L; Soulié C; Peytavin G; Calvez V; Génin MA; Molina JM; Bouchaud O; Katlama C; Costagliola D;
    J Antimicrob Chemother; 2008 Oct; 62(4):797-808. PubMed ID: 18641035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI.
    Torti C; d'Arminio-Monforte A; Pozniak AL; Lapadula G; Cologni G; Antinori A; De Luca A; Mussini C; Castagna A; Cicconi P; Minoli L; Costantini A; Carosi G; Liang H; Cesana BM;
    BMC Infect Dis; 2011 Jan; 11():23. PubMed ID: 21266068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the risks of atherosclerotic events versus death from other causes associated with antiretroviral use.
    Kwong GP; Ghani AC; Rode RA; Bartley LM; Cowling BJ; da Silva B; Donnelly CA; van Sighem AI; Cameron DW; Danner SA; de Wolf F; Anderson RM
    AIDS; 2006 Oct; 20(15):1941-50. PubMed ID: 16988515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-Nucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy in Perinatally HIV-Infected, Treatment-Naïve Adolescents in Asia.
    Boettiger DC; Sudjaritruk T; Nallusamy R; Lumbiganon P; Rungmaitree S; Hansudewechakul R; Kumarasamy N; Bunupuradah T; Saphonn V; Truong KH; Yusoff NKN; Do VC; Nguyen LV; Razali KAM; Fong SM; Kurniati N; Kariminia A
    J Adolesc Health; 2016 Apr; 58(4):451-459. PubMed ID: 26803201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial.
    MacArthur RD; Novak RM; Peng G; Chen L; Xiang Y; Hullsiek KH; Kozal MJ; van den Berg-Wolf M; Henely C; Schmetter B; Dehlinger M; ;
    Lancet; 2006 Dec; 368(9553):2125-35. PubMed ID: 17174704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.